A Sequential Phase 2/3 Study of APL2 in Patients With Focal Segmental Glomerulosclerosis

NCT07213960 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

NOT_YET_RECRUITING

Status

270

Enrollment

INDUSTRY

Sponsor class

Conditions

FSGS

Interventions

DRUG: APL2
OTHER: Placebo

Sponsor

Apellis Pharmaceuticals, Inc.